Obesity is more common in people with inflammatory bowel disease than it used to be, and carrying excess weight is linked with worse IBD outcomes. If you live with ulcerative colitis and are considering Mounjaro, it is reasonable to ask whether it is suitable for you. The answer depends on your health, your colitis, and the advice of your healthcare team.
The honest position is this. Ulcerative colitis is not listed as a contraindication to tirzepatide, and early observational research suggests that GLP 1 medicines may be used in people with IBD without an apparent increase in flares. However, people with IBD were excluded from the main trials, and the prescribing information advises against use in severe gastrointestinal disease. It can also be difficult to tell a colitis flare from a side effect. This page explains what is known and what still needs to be considered.
Key things to know
- Ulcerative colitis is not a listed contraindication, but tirzepatide is not recommended in severe gastrointestinal disease.
- People with IBD were excluded from the main GLP 1 trials, so the evidence is based on observational research rather than randomised trials.
- An injection does not mean the medicine has no effect on your bowel. Tirzepatide can affect gut movement.
- Nausea, diarrhoea, and abdominal pain can also occur during a colitis flare. This can make the symptoms difficult to tell apart.
- Faecal calprotectin can help your healthcare team check for intestinal inflammation, but it does not replace a full clinical assessment.
- Disease activity matters. Well controlled colitis in remission is different from active disease.
Can You Take Mounjaro With Ulcerative Colitis?
Possibly, but this needs an individual clinical assessment. Your IBD team should be involved, not just your weight loss prescriber. Ulcerative colitis does not appear as a contraindication in the Summary of Product Characteristics for Mounjaro.
The prescribing information states that Mounjaro has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients. This is important. It is not a blanket ban on every bowel condition, but it means the severity of your condition and your current disease activity need to be considered.
Someone with long standing colitis in stable remission on maintenance treatment may have a different clinical picture from someone with active inflammation, frequent flares, or a recent hospital admission. Your healthcare team will need to assess which situation applies to you.
A Claim Worth Correcting: Injecting Does Not Bypass Your Bowel
You may read online that because Mounjaro is injected under the skin, it avoids the inflamed digestive tract and is therefore gentler on the bowel than tablets. The first part is true in a narrow sense. The conclusion does not follow.
A subcutaneous injection means the medicine is not absorbed through your gut. This avoids some absorption problems that can affect oral medicines. However, tirzepatide then works throughout the body, and one of its effects is to slow the movement of food through the stomach and change gut motility. Nausea, diarrhoea, constipation, and abdominal discomfort are among its commonly reported side effects.
So, the route of administration avoids one problem but does not remove the possibility of gastrointestinal side effects. If you have ulcerative colitis, these effects need to be considered as part of your treatment assessment.
What the Research Shows About GLP 1 Medication in IBD
People with IBD were excluded from the main GLP 1 trials, so most of what we know about this group comes from observational research carried out afterwards. The findings are encouraging, but they are not the same as evidence from randomised trials and should not be presented as proof of safety or benefit. PubMed Central
What the published evidence currently shows
| Finding | What it means | How strong is it |
|---|---|---|
| GLP 1 use in IBD was not associated with an apparent increase in flares | The main safety concern has not been seen in the available research so far | Systematic review of mostly observational studies |
| Meaningful weight loss achieved in IBD populations | Pooled analyses report useful weight reduction | Meta analysis of observational cohorts |
| Signals of fewer IBD related complications and hospitalisations | There may be a benefit, possibly linked to treating obesity itself | Cohort data, not proof of cause |
| Obesity is associated with worse IBD treatment outcomes | There is a clinical reason to consider weight management in IBD | Registry and cohort evidence |
| A trial of tirzepatide alongside IBD therapy in active ulcerative colitis is under way | The specific question is being studied more directly | Ongoing, results not yet available |
Observational evidence shows an association, not causation. This research does not establish that Mounjaro treats or improves ulcerative colitis, and it is not licensed for that purpose.
Across mainly real world observational studies, GLP 1 use was associated with meaningful weight loss and metabolic improvements without an apparent increase in IBD flares. One pooled analysis reported an average weight change of 5.71kg. ScienceDirect medrxiv
The last row is worth noting. A randomised study is examining tirzepatide alongside an established IBD biologic in people with moderately to severely active ulcerative colitis and obesity or overweight. This study may provide more direct evidence about the treatment combination. Until the results are available, it is not possible to say with certainty how tirzepatide affects active ulcerative colitis.
The Real Difficulty: Telling a Flare From a Side Effect
This is an important practical issue. Mounjaro can cause gastrointestinal side effects, and some of these can look similar to colitis symptoms. It is not always possible to tell them apart from symptoms alone.
Nausea is reported in roughly 12 to 24% of patients and diarrhoea in approximately 13 to 22%, generally more common during dose escalation. Diarrhoea is also a common symptom of active ulcerative colitis. New diarrhoea should not automatically be assumed to be a side effect of the injection.
Overlapping symptoms and what should raise concern
| Symptom | Common with tirzepatide | Also a colitis symptom | What may suggest a flare |
|---|---|---|---|
| Diarrhoea | Yes, commonly reported | Yes, common in active disease | Blood or mucus, waking at night, or increased urgency |
| Abdominal pain | Yes | Yes | Persistent, localised, or severe pain |
| Nausea | Yes, especially when increasing the dose | Less typical on its own | Occurring with fever or bleeding |
| Fatigue | Possible, particularly with reduced food intake | Yes | Alongside bleeding or raised inflammatory markers |
| Constipation | Yes | Can occur in proctitis | New or worsening symptoms that may suggest an obstruction |
Rectal bleeding should not be assumed to be a side effect of a weight loss injection. It is a symptom of ulcerative colitis that needs medical assessment. Contact your IBD team rather than waiting to see whether it settles.
Why faecal calprotectin matters here
Faecal calprotectin measures intestinal inflammation. It can help your healthcare team assess whether symptoms may be linked to active colitis. However, it is not a complete test for every cause of gastrointestinal symptoms, and the result needs to be interpreted alongside your symptoms and other clinical findings.
If you are considering Mounjaro, it may be useful to agree a monitoring plan with your IBD team before you start. This could include a baseline calprotectin result, when to repeat the test, and who to contact if your symptoms change. Your team can also advise whether other tests or inflammatory markers are needed.
Ulcerative Colitis Compared With Crohn's Disease
Both are inflammatory bowel diseases, but they are not identical. Ulcerative colitis affects the lining of the colon and rectum continuously from the rectum upwards. Crohn's disease can affect any part of the digestive tract, affects the full thickness of the bowel wall, and can cause strictures.
This creates a difference worth knowing. Tirzepatide slows gut motility and can cause constipation. There is a theoretical concern about obstructive complications in people with narrowed bowel. A case report described severe small bowel obstruction in a patient taking long term tirzepatide. However, a case report cannot establish that tirzepatide caused the obstruction. The timing of treatment, progressive constipation, and the eventual obstruction suggested that it may have contributed. Stricturing disease is a feature of Crohn's rather than ulcerative colitis, so this concern applies more directly to Crohn's disease. It is still worth discussing with your healthcare team if you have had previous bowel surgery or adhesions.
For ulcerative colitis, the main concerns are symptom overlap, dehydration, and current disease activity.
Comparing Weight Loss Treatments if You Have IBD
A common question is which weight loss medication is best for ulcerative colitis. There is no evidence based answer to that, and no medicine has been shown to be superior in this group. What can be described honestly is how the options differ.
How the main options differ for someone with IBD
| Treatment | How it works | IBD relevant consideration |
|---|---|---|
| Mounjaro (tirzepatide) | Weekly injection, dual GIP and GLP 1 receptor agonist | Slows gastric emptying; gastrointestinal side effects can overlap with flare symptoms |
| Wegovy (semaglutide) | Weekly injection, GLP 1 receptor agonist | Similar gastrointestinal side effects; most IBD observational data involves semaglutide |
| Saxenda (liraglutide) | Daily injection, GLP 1 receptor agonist | Similar gastrointestinal side effects, taken daily rather than weekly |
| Orlistat | Oral medicine that reduces fat absorption in the gut | Commonly causes loose, oily stools and urgency, which may be difficult to manage with colitis |
No comparison here implies that one treatment is better than another. Suitability depends on an individual clinical assessment by an appropriately qualified prescriber.
One practical difference is that orlistat works inside the gut by reducing fat absorption. Its expected effects include loose stools, urgency, and faecal incontinence. These effects may be difficult to manage for anyone and may be particularly unhelpful for someone with ulcerative colitis. GLP 1 medicines also have gastrointestinal side effects, so the choice between them depends on factors such as tolerability, dosing frequency, and clinical suitability.
Your Colitis Medicines and Delayed Stomach Emptying
Tirzepatide slows gastric emptying, which may affect how some oral medicines are absorbed, particularly during the first weeks of treatment and after each increase in strength. Several ulcerative colitis treatments are taken orally, and some mesalazine preparations are designed to release in a specific part of the gut.
There is no established evidence of a clinically significant interaction between tirzepatide and mesalazine, azathioprine, or the biologic therapies used in IBD. Injected biologics are not affected by gastric emptying. Even so, your gastroenterology team should know that you are starting tirzepatide so they can assess whether anything needs monitoring.
One interaction is well established and applies to everyone. Women of childbearing potential should use additional contraception for four weeks after starting tirzepatide and for four weeks after each dose increase, in line with MHRA advice issued in 2025.
Dehydration, Kidney Function and Why It Matters More Here
Prescribing information notes postmarketing reports of acute kidney injury and worsening of chronic renal failure with GLP-1 receptor agonists, with most reported cases occurring in patients who experienced nausea, vomiting, diarrhoea or dehydration. For most users this is a low risk that is managed by keeping fluids up. FDA
If you have ulcerative colitis you may already have periods of increased stool frequency and fluid loss. Adding a medicine whose common side effects include diarrhoea and vomiting stacks two sources of the same risk. Maintaining fluid intake is not optional advice in this situation, and prolonged vomiting or an inability to keep fluids down warrants medical contact rather than waiting.
What Your Prescriber and IBD Team Need to Know
A weight loss consultation is only as safe as the information it is given. If you have ulcerative colitis, disclose all of the following, even if you are worried it will affect approval:
- Your diagnosis, how long you have had it and how extensive it is.
- Whether you are currently in remission, and when your last flare was.
- All IBD medicines you take, including biologics, immunosuppressants and steroids.
- Any previous bowel surgery, strictures, obstruction or stoma.
- Recent inflammatory markers or faecal calprotectin results if you have them.
- Any recent unintentional weight loss, which in IBD is a symptom needing investigation rather than a starting point for weight treatment.
That last point deserves emphasis. Unintended weight loss in inflammatory bowel disease can indicate active disease or malabsorption. It should be investigated by your gastroenterology team before anyone considers a medicine designed to reduce appetite further.
Prices and How Mounjaro Is Supplied
Mounjaro is a prescription-only medicine containing tirzepatide, made by Eli Lilly and given once weekly by subcutaneous injection using the KwikPen device, which delivers four weekly doses per pen. It is licensed for weight management alongside a reduced-calorie diet and increased physical activity, and for type 2 diabetes. It is not licensed to treat ulcerative colitis or any inflammatory bowel disease.
Mounjaro standard prices by strength
| Strength | Standard price per pen (4 weekly doses) | Approximate cost per weekly dose |
|---|---|---|
| 2.5mg | £174.99 | £43.75 |
| 5mg | £204.99 | £51.25 |
| 7.5mg | £254.99 | £63.75 |
| 10mg | £274.99 | £68.75 |
| 12.5mg | £304.99 | £76.25 |
| 15mg | £323.99 | £81.00 |
Standard prices shown for comparison. Prices update live and the price table on the product page always takes precedence. Treatment is subject to consultation and clinical approval.
EveryDayMeds is a UK-registered pharmacy operated by OVIO LTD. Genuine Eli Lilly medication is dispatched with temperature-controlled delivery, since tirzepatide requires refrigerated storage before first use. Treatment is supplied only after clinical assessment by an appropriately qualified UK-registered prescriber, and an existing IBD diagnosis is something that assessment needs to take into account. Availability can change, so check the live status on the product page. You can read more about Mounjaro injections, or see the wider range of medically supervised weight loss options in the weight loss hub.
If you have ulcerative colitis, the sensible order is to speak to your gastroenterology team first and complete a weight loss consultation second. An online assessment cannot see your endoscopy history, your calprotectin trend or your current disease activity. Your IBD team can.
Medical Disclaimer
This article is for general information only. It does not constitute medical advice, a diagnosis, or a recommendation to start any medicine. Mounjaro is a prescription only medicine and should only be used under the supervision of an appropriately qualified prescriber. Whether it is suitable for you depends on your individual clinical assessment, and results vary between individuals.
Mounjaro is not licensed to treat ulcerative colitis, Crohn's disease, or any inflammatory bowel disease. Nothing on this page should be taken to mean that it improves these conditions. Do not start, stop, or change any inflammatory bowel disease treatment based on this page. If you have IBD, speak to your gastroenterology team before starting any weight loss medicine. Seek urgent medical advice if you have rectal bleeding, severe abdominal pain, persistent vomiting, or signs of dehydration.
